Clinical Guideline
Adenosine

Policy developed by: SA Maternal & Neonatal Clinical Community of Practice
Approved by Safety & Quality Strategic Governance Committee on: 28 April 2017
Next review due: 30 April 2020

Summary
The purpose of the Adenosine Neonatal Medication Guideline is to guide nursing, medical and pharmacy staff in the dosing and administration of adenosine.

Keywords
Adenosine, neonatal medication guideline, supraventricular tachycardia, ECG, sinus rhythm, SVT, clinical guideline, Adenosine Neonatal Medication Guideline

Policy history
Is this a new policy? N
Does this policy amend or update an existing policy? Y v1.0
Does this policy replace an existing policy? N
If so, which policies?

Applies to
All Health Networks
CALHN, SALHN, NALHN, CHSALHN, WCHN

Staff impact
All Clinical, Medical, Midwifery, Nursing, Students, Allied Health, Emergency, Mental Health, Pathology, Pharmacy

PDS reference CG005

Version control and change history

<table>
<thead>
<tr>
<th>Version</th>
<th>Date from</th>
<th>Date to</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Nov 2012</td>
<td>April 2017</td>
<td>Original version</td>
</tr>
<tr>
<td>2.0</td>
<td>28 April 2017</td>
<td>Current</td>
<td>Complete review</td>
</tr>
</tbody>
</table>

© Department for Health and Ageing, Government of South Australia. All rights reserved.
Note
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

• The use of interpreter services where necessary,
• Advising consumers of their choice and ensuring informed consent is obtained,
• Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
• Documenting all care in accordance with mandatory and local requirements

This is a High Risk Medication
An overdose can be rapidly fatal.

Dose and Indications

1mg = 1000micrograms
Write all doses in micrograms

To Revert Paroxysmal Supraventricular Tachycardia (SVT)

Intravenous

100micrograms/kg/dose initially, increasing by 50-100 micrograms/kg/dose increments (to a maximum of 300micrograms/kg/dose) every 2 minutes until return of sinus rhythm.

Larger doses may be used after consultation with a paediatric cardiologist.
Preparation and Administration

Intravenous

Withdraw 1mL from a 6mg/2mL adenosine injection and add 9mL of compatible fluid (total volume 10mL) and shake gently to mix. The resulting solution contains 300micrograms/mL.

<table>
<thead>
<tr>
<th>Dose</th>
<th>60 micrograms</th>
<th>90 micrograms</th>
<th>120 micrograms</th>
<th>150 micrograms</th>
<th>180 micrograms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.2mL</td>
<td>0.3mL</td>
<td>0.4mL</td>
<td>0.5mL</td>
<td>0.6mL</td>
</tr>
</tbody>
</table>

For small volumes dilute with 1 to 2mL of sodium chloride 0.9%

Administer into a large vein as a rapid intravenous push (over 1 to 2 seconds) and follow with a rapid sodium chloride 0.9% flush.

Discard diluted solution immediately after use.

Do not refrigerate.

Compatible Fluids

Glucose 5%, sodium chloride 0.9%

Adverse Effects

Adverse effects resolve rapidly on stopping treatment due to its short duration of action.

Common

Flushing, dyspnoea

Infrequent

Transient arrhythmias, hypotension

Monitoring

> Adenosine should only be used when facilities for cardiac monitoring and cardiorespiratory resuscitation exist.
> Continuous electrocardiogram (ECG) is required.
> Blood pressure
Practice Points

> Larger doses may be required in patients receiving caffeine
> Doses must be given by rapid intravenous push. Inject dose as close to intravenous site as possible with sufficient flush volume to ensure the bolus dose is administered to patient (and not still contained in the line)
> Adenosine has a very short duration of effect (half-life of less than 10 seconds) making it necessary to give this agent as a rapid bolus
> Diluting the ampoule assists with drawing up an accurate dose. Large doses may be given undiluted

Reference

Version control and change history

**PDS reference:** OCE use only

<table>
<thead>
<tr>
<th>Version</th>
<th>Date from</th>
<th>Date to</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Nov 2012</td>
<td>April 2017</td>
<td>Original version</td>
</tr>
<tr>
<td>2.0</td>
<td>April 2017</td>
<td>Current</td>
<td>Complete review</td>
</tr>
</tbody>
</table>